SCHEMBL12676402

SCHEMBL12676402

NC(=O)c1cn([C@@H]2O[C@H](CO)C(O)C2O)cn1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
ALDH1A1 P00352 3/20 0.57
TSHR P16473 2/20 0.57
THPO P40225 2/20 0.57
PMP22 Q01453 2/20 0.57
ADORA1 P30542 2/20 0.57
GLA P06280 1/20 0.57
EIF4E P06730 1/20 0.57
CYP3A4 P08684 1/20 0.57
TOP1 P11387 1/20 0.57
KDM4E B2RXH2 2/20 0.56
HTT P42858 2/20 0.56
BLM P54132 2/20 0.56
TP53 P04637 2/20 0.56
MAPT P10636 2/20 0.56
TDP1 Q9NUW8 1/20 0.56
GAA P10253 1/20 0.56
PNP P00491 2/20 0.48
GMNN O75496 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6385747 1.00 LMNA (0.57) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL2481555 1.00 LMNA (0.57) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL7213155 1.00 LMNA (0.57) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL12669988 1.00 LMNA (0.57) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL8722885 1.00 LMNA (0.57) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL15916868 0.87 LMNA (0.49) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL28863454 0.84 TP53 (0.48) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL17993314 0.83 LMNA (0.46) LMNASMN1; SMN2ALDH1A1TSHRTHPO
SCHEMBL24024486 0.82 ATIC (0.62) SMN1; SMN2ADORA1
SCHEMBL29687021 0.82 ATIC (0.62) SMN1; SMN2ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110117054-A1 USE OF RIBAVIRIN IN BLOOD COAGULATION DISORDER NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) 2011-05-19 US disclosed
US-20110045535-A1 Activator for Blood Coagulation Factor VII Promoter and Utilization of the Same NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) 2011-02-24 US disclosed
EP-2201953-A1 USE OF RIBAVIRIN IN BLOOD COAGULATION DISORDER National University Corporation Nagoya University (JP) 2010-06-30 EP disclosed
EP-2198870-A1 ACTIVATOR FOR BLOOD COAGULATION FACTOR VII PROMOTER AND UTILIZATION OF THE SAME National University Corporation Nagoya University (JP) 2010-06-23 EP disclosed
US-20100129317-A1 AZOLE NUCLEOSIDES AND USE AS INHIBITORS OF RNA AND DNA VIRAL POLYMERASES SOUTHERN RESEARCH INSTITUTE (US) 2010-05-27 US disclosed
WO-2008067002-A2 AZOLE NUCLEOSIDES AND USE AS INHIBITORS OF RNA AND DNA VARIAL POLYMERASES SOUTHERN RESEARCH INSTITUTE (US) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100129317-A1 AZOLE NUCLEOSIDES AND USE AS INHIBITORS OF RNA AND DNA VIRAL POLYMERASES RNASEH1, RNASEL, POLR2E LMNA 739/4885SMN1; SMN2 3616/4885ALDH1A1 2684/4885
US-20110045535-A1 Activator for Blood Coagulation Factor VII Promoter and Utilization of the Same F7, F8, HABP2 LMNA 2396/4885SMN1; SMN2 3898/4885ALDH1A1 2278/4885
US-20110117054-A1 USE OF RIBAVIRIN IN BLOOD COAGULATION DISORDER F2, SERPINC1, F8 LMNA 1195/4885SMN1; SMN2 864/4885ALDH1A1 1403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.